ABSTRACT Nifedipine (10 mg qid) and captopril (25 mg qid) were tested alone and in combination in 14 patients suffering from severe primary hypertension. Each study period was of 1 week's duration. Circulatory response was evaluated through hourly pressure and pulse rate readings. The fall in pressure after oral nifedipine was maximal within 1 hr or less and was generally accompanied by palpitation and increase in pulse rate; with a six hourly dosing regimen the tendency of blood pressure to recover after each dose was interrupted by the next dose, so that values remained significantly reduced throughout the 24 hr, although pressure fluctuations were evident. Promptness of the antihypertensive action of captopril was similar, but the magnitude and the duration of the fall in pressure were less pronounced. When the converting-enzyme inhibitor was combined with the calcium-channel blocker, pressure fluctuations were not abolished, but the antihypertensive response was definitely enhanced, so that normal blood pressure was maintained for several hours during the day. Additional positive effects of captopril were mitigation of the heart rate reaction and prevention of the ankle pitting or edema elicited by nifedipine. A balance in arteriolar and venular dilatation promoted by captopril is the suggested mechanism for these effects. With the two-drug combination the function of the left ventricle was not reduced and possibly improved; blood urea nitrogen and serum electrolyte and creatinine concentration were not affected. Plasma renin activity increased with captopril and reverted toward baseline with the addition of nifedipine, suggesting an interference of the calcium-channel blocker with the release of renin. Circulation 70, No. 2, 279-284, 1984. CALCIUM ANTAGONISTS block transmembrane Ca supply and reduce the contractile vascular muscle activity in a dose-related manner. However, the higher the wall tension is elevated above normal, the more relaxation is induced by a given concentration of Ca antagonist.' Because of this, the use of these compounds has been proposed in the management of hypertensive crises2 as well as in the treatment of essential hypertension.3 The hypotensive response to oral nifedipine is prompt, and a dosing regimen every 6 hr significantly lowers blood pressure over the 24 hr, although fluctuations are recorded owing to the rate of decay of the vasodilating effect.4 The reaction of pulse rate at the nadir of the hypotensive response to each
CALCIUM ANTAGONISTS block transmembrane Ca supply and reduce the contractile vascular muscle activity in a dose-related manner. However, the higher the wall tension is elevated above normal, the more relaxation is induced by a given concentration of Ca antagonist.' Because of this, the use of these compounds has been proposed in the management of hypertensive crises2 as well as in the treatment of essential hypertension.3 The hypotensive response to oral nifedipine is prompt, and a dosing regimen every 6 hr significantly lowers blood pressure over the 24 hr, although fluctuations are recorded owing to the rate of decay of the vasodilating effect. 4 The reaction of pulse rate at the nadir of the hypotensive response to each dose and development of ankle edema in about 25% of the patients are additional unwanted effects. Combination with methyldopa5 or propranolol6 potentiates the efficacy of nifedipine and reduces tachycardia and pressure fluctuations, but does not prevent ankle edema. In addition, although it has been proved that nifedipine does not depress the performance of the heart in an important way when the authonomic nervous system is intact, combination with a fl-blocker may expose the patient to the potential hazard of excessive depression in contractility7 when the baseline heart function is impaired. 8 Captopril lowers blood pressure9 without eliciting tachycardia and also improves the function of the failing heart.'0 In two severely hypertensive patients whose disease responded poorly to nifedipine, the addition of captopril potentiated the Jndicates differences from baseline significant at p < .01 by the converting-enzyme inhibitor compared with during the nifedipine period without associated changes in body weight and urinary output. Plasma renin activity in subjects in the supine and standing positions did not differ significantly from control after nifedipine, was remarkably increased after captopril, and reverted toward baseline after the combination of the drugs.
No noticeable side effect of captopril was observed or reported.
Discussion
Both nifedipine' and captopril'6 are basically vasodilators and they lower blood pressure2' 17 through reduction of peripheral vascular resistance. As antihypertensive drugs, they seem best suited for treating patients with a high degree of vasoconstriction, who generally present with remarkable elevation of the diastolic blood pressure.',' [18] [19] [20] [21] A dosing regimen of 25 mg qid captopril has proved to possess definite antihypertensive efficacy with minimal side effects20' 22, 23; no side effects of captopril were noted in the present trial. Comparing period A in group 1 and C in group 2 (nifedipine) with period A in group 2 and C in group 1 (captopril) we observed the following: the time for maximal pressure lowering was similar for captopril and oral nifedipine, nifedipine was more potent,24 and the slopes of recovery of blood pressure and, consequently, the rates of decay of the vasodilatation were comparable, although the mechanism of the vasodilating action was likely very much different. Because the two drugs are of disparate antihypertensive efficacy while there is a similar decay of their vasodilatatory effects, 6 hr after each dose pressure reduction was invariably significant with nifedipine, while differences from control were only of borderline significance with captopril (group 2, period A). This suggests that with a three-times-daily dosing regimen, which is currently used for captopril, pressure may remain elevated for a certain span over the 24 hours of the day. Also, at least over a short-term period, both preparations maintained their efficacy; period C was characterized, in both group 1 and group 2, by a consistent increase in pressure compared with period B.
The mechanism through which vasodilatation is induced and blood pressure is lowered by captopril is not completely understood; inhibition of angiotensin II production, increase in the circulating levels of bradykinin, enhanced release of prostaglandins,'6 and depression of a-adrenergic responsiveness in vascular smooth muscle25 seem to be involved. Whatever the mechanisms are, they must be active in the presence of calcium-channel blockade. With regard to the relationship between calcium and the renin-angiotensin system, it is documented that the former is involved in the control of renin release26 and that calcium antagonists, unlike other vasodilators, do not promote hyperreninemia. 1 4, 27 In this study, plasma renin activity was enhanced by the converting-enzyme inhibitor'6 and was brought back toward baseline (table 1) by the addition of nifedipine, indicating a negative interference of this compound with the release of renin.
Captopril reduced the reaction of heart rate to nifedipine and exerted a beneficial effect on the ankle pitting or edema promoted by the calcium-channel blocker. The pulse rate restraint might have been due to withdrawal of the facilitating action of angiotensin II on the sympathetic neurotransmission; however, this interpretation is not supported by the changes that captopril, both alone and in combination, induced on the relationship of the end-systolic stress vs left ventricular end-systolic diameter,28' which was taken as an index of the end-systolic force-length relationship.'4 The shift to the left of baseline (figure 2) in this relationship, in fact, rules out a negative inotropic influence, which would be expected if sympathetic neurotransmission were impaired. Other pharmacologic actions of the converting-enzyme inhibitor may be responsible, such as its modification of arterial baroreflexes30 and the venodilatation it induces'7 (if blood pressure falls from balanced arterial and venodilatation, resulting heart rate may not vary).
Changes from baseline that were observed in the force-length relationship may indicate either a shift to a different point in the same basal stress-length line (which would indicate no change in contractility) or a displacement to the left of the stress-length line itself (which would reflect improved contractility). It is worthwhile to note that the decrease in stress was comparable after the three different drug regimens, while reduction in ventricular end-systolic dimension was greater when captopril was used alone or combined with nifedipine. This pattern favors the interpretation that the force-length line was shifted to the left by the converting-enzyme inhibitor and suggests that the nifedipine-captopril combination may also be used with a reasonable amount of confidence in patients with advanced hypertensive heart disease.
The tendency to ankle pitting or edema in patients on nifedipine is probably not related to the hypertensive state, since it may also appear in patients with normal blood pressure who are treated with nifedipine for angina pectoris. It has also been documented that the mechanism of this effect is independent of fluid retention or cardiac function depression.5 Perhaps arteriolar vasodilatation without venular dilatation increases capillary pressure, which adds to gravitational effects, resulting in edema. Possible explanations for the beneficial influence of captopril can only be speculative given the presently available data. Apart from the humoral actions of the compound that make it a useful remedy for idiopathic edema,3' the venodilatation it induces might substantially contribute to counteract this unwanted effect.
The combination of a calcium blocker and the converting-enzyme inhibitor, if properly used, appears to be more effective and better suited than each drug alone for treating patients with severe hypertension with high-level diastolic pressure and vasoconstriction. Persistence of efficacy is being evaluated through a long-term follow-up trial.
